Drug Profile
Debio 1452
Alternative Names: AFN 1252; AFN-12520000; API 1252Latest Information Update: 07 May 2018
Price :
$50
*
At a glance
- Originator Affinium Pharmaceuticals
- Developer Debiopharm Group
- Class Anti-infectives; Small molecules
- Mechanism of Action Enoyl-ACP reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Skin and soft tissue infections
- No development reported Bacterial infections
Most Recent Events
- 21 Apr 2018 Pharmacodynamic data from Skin and soft tissue infections presented at the Annual Meeting of the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in Canada (PO, Tablet)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV, Injection)